Syndax Pharmaceuticals Inc [SNDX] stock is trading at $9.85, up 2.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have gain 12.83% over the last week, with a monthly amount drifted -9.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $18. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $37. On June 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $37 on the stock. Scotiabank downgraded its rating to a Sector Perform and decreased its price target to $23 on January 31, 2024. Mizuho initiated its recommendation with a Buy and recommended $45 as its price target on December 22, 2023. BofA Securities started tracking with a Buy rating for this stock on October 25, 2023, and assigned it a price target of $29. In a note dated October 11, 2023, Goldman initiated an Buy rating and provided a target price of $30 on this stock.
Syndax Pharmaceuticals Inc [SNDX] stock has fluctuated between $8.58 and $25.07 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $9.85 at the most recent close of the market. An investor can expect a potential return of 82.74% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -7.87%, Pretax Profit Margin comes in at -7.58%, and Net Profit Margin reading is -7.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -1.02 and Total Capital is -0.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.63 points at the first support level, and at 9.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.97, and for the 2nd resistance point, it is at 10.09.
Ratios To Look Out For
For context, Syndax Pharmaceuticals Inc’s Current Ratio is 5.80. As well, the Quick Ratio is 5.75, while the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 19.39, the price to book ratio is 3.94.
Transactions by insiders
Recent insider trading involved Gallagher Neil, Officer, that happened on Jul 10 ’25 when 9679.0 shares were purchased. Head of R&D, CMO, Botwood Nicholas A.J. completed a deal on May 16 ’25 to buy 11765.0 shares. Meanwhile, Director Huber Martin H. Jr. bought 5000.0 shares on May 19 ’25.
